↓ Skip to main content

The clinical and functional significance of c-Met in breast cancer: a review

Overview of attention for article published in Breast Cancer Research, April 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
2 patents

Citations

dimensions_citation
152 Dimensions

Readers on

mendeley
156 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The clinical and functional significance of c-Met in breast cancer: a review
Published in
Breast Cancer Research, April 2015
DOI 10.1186/s13058-015-0547-6
Pubmed ID
Authors

Colan M Ho-Yen, J Louise Jones, Stephanie Kermorgant

Abstract

c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor is regarded as a novel therapeutic target. In breast cancer there is a need to develop new treatments, particularly for the aggressive subtypes such as triple-negative and basal-like cancer, which currently lack targeted therapy. Over the last two decades, much has been learnt about the functional role of c-Met signalling in different models of breast development and cancer. This work has been complemented by clinical studies, establishing the prognostic significance of c-Met in tissue samples of breast cancer. While the clinical trials of anti-c-Met therapy in advanced breast cancer progress, there is a need to review the existing evidence so that the potential of these treatments can be better appreciated. The aim of this article is to examine the role of HGF/c-Met signalling in in vitro and in vivo models of breast cancer, to describe the mechanisms of aberrant c-Met signalling in human tissues, and to give a brief overview of the anti-c-Met therapies currently being evaluated in breast cancer patients. We will show that the HGF/c-Met pathway is associated with breast cancer progression and suggest that there is a firm basis for continued development of anti-c-Met treatment, particularly for patients with basal-like and triple-negative breast cancer.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Austria 1 <1%
Unknown 154 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 40 26%
Researcher 19 12%
Student > Bachelor 18 12%
Student > Master 15 10%
Student > Doctoral Student 10 6%
Other 23 15%
Unknown 31 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 37 24%
Agricultural and Biological Sciences 34 22%
Medicine and Dentistry 24 15%
Chemistry 6 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 3%
Other 15 10%
Unknown 36 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2019.
All research outputs
#8,534,976
of 25,374,647 outputs
Outputs from Breast Cancer Research
#977
of 2,052 outputs
Outputs of similar age
#97,753
of 279,941 outputs
Outputs of similar age from Breast Cancer Research
#24
of 46 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,941 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.